NCT04858750

Brief Summary

Indwelling double-J ureteral stent (D-J stent) are routinely placed in patients who received ureteroscopic lithotripsy (URL) in Xinhua Hospital Urology Department. At present, three types of D-J stents, namely Cook/Kang Yi Bo(KYB)/Urovisionare are used, and usually removed in the day ward four weeks after surgery. This study intends to randomly divide patients with urolithiasis based on the preoperative OABSS (overactive bladder symptom score) questionnaire into three groups, namely Cook D-J stent group, KYB anti-reflux D-J stent group, Urovision trigonal D-J stent group, with corresponding D-J stent indwelled for 4 weeks respectively. The patient's USSQ ureteral stent symptom questionnaire)scale and OABSS scale were collected at 1 week, 4 weeks (before the removal of D-J stents), and 5 weeks (1 week after removal of D-J stents) after URL operation, and the D-J stents removed from the patients were collected, and their drainage and anti-reflux effects were measured in vitro.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 14, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 26, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2023

Completed
Last Updated

March 22, 2022

Status Verified

February 1, 2022

Enrollment Period

2.2 years

First QC Date

April 14, 2021

Last Update Submit

March 19, 2022

Conditions

Keywords

USSQOABSSdouble-J stentureteroscopic holmium laser lithotripsy

Outcome Measures

Primary Outcomes (6)

  • Hematuria, lower urinary tract symptoms and other aspects after placement of D-J stent

    The patients' symptoms are evaluated by complete USSQ (Ureteral Stent Symptom Questionnaire)

    1 week (after URL)

  • Hematuria, lower urinary tract symptoms and other aspects after placement of D-J stent

    The patients' symptoms are evaluated by OABSS ( Overactive Bladder Symptom Score) scale.

    1 week (after URL)

  • Hematuria, lower urinary tract symptoms and other aspects after placement of D-J stent

    The patients' symptoms are evaluated by complete USSQ (Ureteral Stent Symptom Questionnaire)

    4 weeks (before removal of D-J stent)

  • Hematuria, lower urinary tract symptoms and other aspects after placement of D-J stent

    The patients' symptoms are evaluated by OABSS ( Overactive Bladder Symptom Score) scale.

    4 weeks (before removal of D-J stent)

  • Hematuria, lower urinary tract symptoms and other aspects after placement of D-J stent

    The patients' symptoms are evaluated by complete USSQ (Ureteral Stent Symptom Questionnaire)

    5 weeks (1 week after removal of D-J stent)

  • Hematuria, lower urinary tract symptoms and other aspects after placement of D-J stent

    The patients' symptoms are evaluated by OABSS ( Overactive Bladder Symptom Score) scale.

    5 weeks (1 week after removal of D-J stent)

Secondary Outcomes (2)

  • Drainage effect of D-J stents after being removed

    4 weeks

  • Anti-reflux effect of D-J stents after being removed

    4 weeks

Study Arms (3)

Cook D-J stent group

OTHER

Patients randomized to this group received Cook (Limerick, Ireland, USI-626-R) D-J stent. Note: USI is an unexpandable acronym.

Device: Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy

KYB anti-reflux D-J stent group

OTHER

Patients randomized to this group received KYB (Shenzhen, China, 3201162) anti-reflux D-J stent.

Device: Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy

Urovision trigonal D-J stent group

OTHER

Patients randomized to this group received Urovision (Bad Aibling, Germany, ST-230726) trigonal D-J stent. Note: ST is an unexpandable acronym. Aibling is a German region name.

Device: Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy

Interventions

During ureteral holmium laser lithotripsy operation, after the stones were fragmented, the D-J stents of three different types were placed, the insertion process are exactly the same.

Cook D-J stent groupKYB anti-reflux D-J stent groupUrovision trigonal D-J stent group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Abdominal CT scanning indicating ureteral stones or kidney stones that are less than 2 cm in diameter, and patients who are planning to undergo URL surgery.
  • Age between 18 and 80 years old and capable of providing written informed consent;
  • In general, the heart, lung, liver and kidney function are in well condition, able to tolerate surgical treatment, and comply with research requirements.

You may not qualify if:

  • Before the onset of urolithiasis, the patient has suffered from obvious overactive bladder syndrome, or chronic lower urinary tract infection, or urinary anatomic deformities, or had previously undergone urinary tract plastic surgery.
  • Other severe complications, infections, etc. that the researchers believe may make the subject unsuitable for this study.
  • The patient is not a local resident and insists on returning to his howetown for D-J stent removal after the URL operation(so that we are unable to retrieve the D-J stent and conduct the in vitro experiment).
  • The patient refuses to sign the informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200092, China

RECRUITING

MeSH Terms

Conditions

Urolithiasis

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 14, 2021

First Posted

April 26, 2021

Study Start

February 1, 2021

Primary Completion

April 30, 2023

Study Completion

May 31, 2023

Last Updated

March 22, 2022

Record last verified: 2022-02

Locations